- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 8,512
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- JNJ-38431055 Dose 1, Sitagliptin 100 mg, Placebo, JNJ-38431055 Dose 2
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 25 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Technosphere insulin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- PB-119 100 μg+ Glucophage®, PB-119 150 μg+ Glucophage®, PB-119 200 μg+ Glucophage®, PB-119 placebo + Glucophage®
- Drug
- Lead sponsor
- PegBio Co., Ltd.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetes
- Interventions
- Linagliptin, Sulfonylurea
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 101,830 participants
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vitamin D Deficiency, Metabolic Syndrome, Prediabetes
- Interventions
- Mushroom with 600 IU vitamin D2, Mushroom with 4000 IU Vitamin D2, 600 IU Vitamin D3 and untreated mushroom, 4000 IU Vitamin D3 and untreated mushroom, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin, Glimepiride, Rosiglitazone, Metformin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 1,791 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 17 more
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
- Interventions
- Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Type 2 Diabetes
- Interventions
- Mitoglitazone, Pioglitazone, Placebo
- Drug
- Lead sponsor
- Metabolic Solutions Development Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more
- Conditions
- Diabetes Mellitus, Type 2, Obesity
- Interventions
- Mobile and connected health
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Mild Cognitive Impairment
- Interventions
- Aerobic exercise
- Behavioral
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Seattle, Washington • Tacoma, Washington
- Conditions
- Spinal Cord Injuries
- Interventions
- Low-frequency Exercise, High-frequency Exercise
- Other
- Lead sponsor
- Richard K Shields
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Diabetes, Kidney Disease, Hypertension
- Interventions
- losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetes Mellitus, Type 2, Obesity
- Interventions
- Gastric bypass, Sleeve Gastrectomy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Diabetic Foot Ulcers
- Interventions
- ofloxacin, MSI-78
- Drug
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 1996
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Gastroparesis With Diabetes Mellitus
- Interventions
- FreeStyle Libre 3 continuous glucose monitoring sensor, Nutritional drink
- Device · Other
- Lead sponsor
- Samita Garg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Healthy Participants
- Interventions
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- PreDiabetes
- Interventions
- Flaxseed High Dose, Flaxseed Low Dose
- Dietary Supplement
- Lead sponsor
- University of Colorado, Colorado Springs
- Other
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Colorado Springs, Colorado • Missoula, Montana
- Conditions
- Impaired Glucose Tolerance, Obesity, Diabetes
- Interventions
- Physical Activity Counseling
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 60 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Chula Vista, California • San Antonio, Texas
- Conditions
- Diabetic Retinopathy (DR)
- Interventions
- Fundus Image Grading
- Diagnostic Test
- Lead sponsor
- Artelus AI
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Oxford, North Carolina • Raleigh, North Carolina
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Active Comparator: Omnipod M System with lower starting dose, Active Comparator: Omnipod M System with higher starting dose
- Device
- Lead sponsor
- Insulet Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
- Interventions
- Dietary supplement for weight loss, Education and counseling for weight loss
- Drug · Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Painful Diabetic Neuropathy
- Interventions
- Nerve Decompression
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas